Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Official Title: A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo.
In Brief: Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks
Ages Eligible: 18 Years to 70 Years
Start Date: September 25, 2019
Completion Date (estimated): July 2020
Status: Active, recruiting
- ClinicalTrials.gov: NCT04103060
- Other Study ID Numbers: DMVT-502-2101
Location: Dermavant Investigational Site: Worcester, Massachusetts, United States, 01605
Contact: To learn more about this study, you or your doctor may contact Dermavant Sciences by phone +1-480-666-0844 or email email@example.com. Please refer to this study by its ClinicalTrials.gov identifier (NCT number)
- How can I cure vitiligo?
There is no cure for vitiligo, but there are a number of effective treatment options that can be discussed with your GP or dermatologist. The aim of treatment is to stop new pat...
- Which skin conditions can be mistaken for vitiligo?
Vitiligo is a common skin condition with characteristic milky white patches of irregular shape. However, several other skin conditions exhibit similar symptoms that can lead to ...
- Can chemicals cause vitiligo?
It’s important to remember there are multiple factors involved in vitiligo onset, including genetic predisposition, living and working environments, and exposure to certain chem...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.